Kennebec Savings Bank Acquires New Stake in Becton, Dickinson and Company (NYSE:BDX)

by · The Cerbat Gem

Kennebec Savings Bank acquired a new stake in Becton, Dickinson and Company (NYSE:BDX – Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 192 shares of the medical instruments supplier’s stock, valued at approximately $46,000.

Several other large investors also recently added to or reduced their stakes in BDX. Empowered Funds LLC grew its holdings in Becton, Dickinson and Company by 40.2% in the 1st quarter. Empowered Funds LLC now owns 4,439 shares of the medical instruments supplier’s stock valued at $1,098,000 after buying an additional 1,273 shares in the last quarter. NorthRock Partners LLC purchased a new stake in Becton, Dickinson and Company in the 1st quarter valued at $205,000. Avantax Advisory Services Inc. grew its holdings in Becton, Dickinson and Company by 5.0% in the 1st quarter. Avantax Advisory Services Inc. now owns 6,354 shares of the medical instruments supplier’s stock valued at $1,572,000 after buying an additional 301 shares in the last quarter. Edmond DE Rothschild Holding S.A. purchased a new stake in Becton, Dickinson and Company in the 1st quarter valued at $148,000. Finally, Entropy Technologies LP grew its holdings in shares of Becton, Dickinson and Company by 374.7% during the 1st quarter. Entropy Technologies LP now owns 15,225 shares of the medical instruments supplier’s stock worth $3,767,000 after purchasing an additional 12,018 shares during the period. 86.97% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

BDX has been the subject of a number of research analyst reports. Stifel Nicolaus increased their price target on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. StockNews.com upgraded Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Evercore ISI raised their target price on Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a report on Tuesday, October 1st. Raymond James lowered their target price on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a report on Friday, August 2nd. Finally, Citigroup upgraded Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and raised their target price for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $283.00.

View Our Latest Research Report on BDX

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $234.73 on Tuesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.36 and a current ratio of 1.17. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $249.89. The firm has a market capitalization of $67.85 billion, a PE ratio of 39.52, a price-to-earnings-growth ratio of 1.73 and a beta of 0.43. The stock’s 50-day simple moving average is $237.04 and its 200-day simple moving average is $235.10.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last issued its earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business had revenue of $5.44 billion for the quarter, compared to analyst estimates of $5.38 billion. During the same quarter last year, the company earned $3.42 EPS. The business’s quarterly revenue was up 6.9% on a year-over-year basis. As a group, equities research analysts forecast that Becton, Dickinson and Company will post 14.37 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Shareholders of record on Monday, December 9th will be paid a $1.04 dividend. This is an increase from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 annualized dividend and a dividend yield of 1.77%. The ex-dividend date of this dividend is Monday, December 9th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 70.03%.

Becton, Dickinson and Company Profile

(Free Report)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

Featured Articles